{"id":"F2023L00001","name":"Statement of Principles concerning malignant neoplasm of the prostate (Reasonable Hypothesis) (No. 3 of 2023)","slug":"statement-of-principles-concerning-malignant-neoplasm-of-the-prostate-reasonable-hypothesis-no-3-of-","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":103672,"registerId":"commonwealth-F2023L00001-current","compilationNumber":null,"startDate":"2026-04-03","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning malignant neoplasm of the prostate (Reasonable Hypothesis) (No. 3 of 2023)","content":"![Commonwealth Coat of Arms](image.001.png)\n\nStatement of Principles concerning malignant neoplasm of the prostate (Reasonable Hypothesis) (No. 3 of 2023)\n\nmade under subsection 196B(2) of the\n\nVeterans' Entitlements Act 1986\n\nCompilation No. 1\n\nCompilation date: 26 March 2024\n\nIncludes amendments: Amendment Statement of Principles concerning factors relating to being in Vietnam (Reasonable Hypothesis) (No. 27 of 2024) (F2024L00224)\n\nThe day of commencement of this Amendment Statement of Principles concerning factors relating to being in Vietnam is 26 March 2024.\n\nAbout this compilation\n\nThis compilation\n\nThis is a compilation of the Statement of Principles concerning malignant neoplasm of the prostate (Reasonable Hypothesis) (No. 3 of 2023) that shows the text of the law as amended and in force on 26 March 2024.\n\nThe notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.\n\nUncommenced amendments\n\nThe effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.\n\nApplication, saving and transitional provisions for provisions and amendments\n\nIf the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.\n\nModifications\n\nIf the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.\n\nSelf‑repealing provisions\n\nIf a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.\n\nContents\n\n1 Name\n\n3 Authority\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\nEndnotes\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\n  \n\n1 Name\n\nThis is the Statement of Principles concerning malignant neoplasm of the prostate (Reasonable Hypothesis) (No. 3 of 2023).\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about malignant neoplasm of the prostate and death from malignant neoplasm of the prostate .\n\nMeaning of malignant neoplasm of the prostate\n\n(2) For the purposes of this Statement of Principles, malignant neoplasm of the prostate:\n\n(a) means a primary malignant neoplasm arising from the epithelial cells of the prostate gland; and\n\n(b) includes high grade prostatic intraepithelial neoplasia; and\n\n(c) excludes:\n\n(i) haematolymphoid tumours (including non-Hodgkin lymphoma and Hodgkin lymphoma);\n\n(ii) low grade prostatic intraepithelial neoplasia;\n\n(iii) malignant melanoma;\n\n(iv) mesenchymal tumours (including soft tissue sarcoma); and\n\n(v) primary neuroendocrine tumours.\n\n(3) While malignant neoplasm of the prostate attracts ICD‑10‑AM code C61, in applying this Statement of Principles the meaning of malignant neoplasm of the prostate is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from malignant neoplasm of the prostate\n\n(5) For the purposes of this Statement of Principles, malignant neoplasm of the prostate, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the prostate.\n\n> Note: terminal event is defined in the Schedule 1 – Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that malignant neoplasm of the prostate and death from malignant neoplasm of the prostate can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\n> Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the prostate or death from malignant neoplasm of the prostate with the circumstances of a person's relevant service:\n\n(1) inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD):\n\n(a) for a cumulative period of at least 1,000 hours, within a consecutive period of 10 years, before the clinical onset of malignant neoplasm of the prostate; and\n\n(b) where the first exposure occurred at least 5 years before the clinical onset of malignant neoplasm of the prostate;\n\n> Note: inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) is defined in the Schedule 1 - Dictionary\n\n(2) being:\n\n(a) on land in Vietnam; or\n\n(b) at sea in Vietnamese waters; or\n\n(c) on board a vessel and consuming potable water supplied on that vessel, when the water supply had been produced by evaporative distillation of estuarine Vietnamese waters; for a cumulative period of at least 30 days, at least 5 years before the clinical onset of malignant neoplasm of the prostate;\n\n> Note: being:\n\n> Note: (a) on land in Vietnam; or\n\n> Note: (b) at sea in Vietnamese waters, estuarine Vietnamese waters and potable water are defined in the Schedule 1 - Dictionary.\n\n(3) consuming an average of at least 400 grams per day of dairy products, for at least 5 years within the 20 years before the clinical onset of malignant neoplasm of the prostate;\n\n(4) being exposed to arsenic as specified before the clinical onset of malignant neoplasm of the prostate, where the first exposure to arsenic occurred at least 10 years before the clinical onset of malignant neoplasm of the prostate;\n\n> Note: being exposed to arsenic as specified is defined in the Schedule 1 - Dictionary.\n\n(5) inhaling fumes, vapours or dusts containing hexavalent chromium (chromium VI), while working in an industry or manufacturing process generating high concentrations of hexavalent chromium compounds:\n\n(a) for a cumulative period of at least 1,500 hours before the clinical onset of malignant neoplasm of the prostate; and\n\n(b) where the first inhalation of fumes, vapours or dusts occurred at least 5 years before the clinical onset of malignant neoplasm of the prostate;\n\n> Note: Examples of industrial processes or workplace practices where exposure to hexavalent chromium compounds can occur include working in the manufacturing or handling of stainless steel, working as a mason or concrete worker dealing with cement that contains chromates, and work involving chromate production and chromate electroplating.\n\n(6) having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the prostate at least 5 years before the clinical onset of malignant neoplasm of the prostate;\n\n> Note: cumulative equivalent dose is defined in the Schedule 1 – Dictionary.\n\n(7) having periodontitis for at least 5 years within the 20 years before the clinical onset of malignant neoplasm of the prostate;\n\n(8) consuming alcohol in an amount of at least 100 kilograms within any 10 year period before the clinical worsening of malignant neoplasm of the prostate;\n\n> Note: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink.\n\n(9) having smoked tobacco products:\n\n(a) in an amount of at least 10 pack-years before the clinical worsening of malignant neoplasm of the prostate; and\n\n(b) commencing at least 5 years before the clinical worsening of malignant neoplasm of the prostate; and\n\nif smoking has ceased before the clinical worsening of malignant neoplasm of the prostate, then that worsening occurred within 20 years of cessation;\n\n> Note: one pack-year is defined in the Schedule 1 – Dictionary.\n\n(10) the use of smokeless tobacco:\n\n(a) on more days than not; and\n\n(b) for at least 10 years before the clinical worsening of malignant neoplasm of the prostate; and\n\nif the use of smokeless tobacco has ceased before the clinical worsening of malignant neoplasm of the prostate, then that worsening occurred within 10 years of cessation;\n\n> Note: smokeless tobacco is defined in the Schedule 1 - Dictionary.\n\n(11) being obese for at least 5 years within the 20 years before the clinical worsening of malignant neoplasm of the prostate;\n\n> Note: being obese is defined in the Schedule 1 – Dictionary.\n\n(12) having diabetes mellitus for at least 5 years before the clinical worsening of malignant neoplasm of the prostate;\n\n(13) inability to obtain appropriate clinical management for malignant neoplasm of the prostate .\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(8) to 9(13) apply only to material contribution to, or aggravation of, malignant neoplasm of the prostate where the person's malignant neoplasm of the prostate was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\nSchedule 1 \\- Dictionary\n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\nbeing exposed to arsenic as specified means:\n\n(a) consuming drinking water with an average arsenic concentration of at least 50 micrograms per litre for a cumulative period of at least 10 years; or\n\n(b) consuming drinking water resulting in a cumulative total arsenic exposure equivalent to having consumed drinking water containing at least 50 micrograms per litre for at least 10 years; or\n\n(c) having clinical evidence of chronic arsenic toxicity.\n\nbeing obese means:\n\n(a) having a Body Mass Index (BMI) of 30 or greater; or\n\n(b) for males, having a waist circumference exceeding 102 centimetres; or\n\n(c) for females, having a waist circumference exceeding 88 centimetres.\n\n> Note: BMI is also defined in the Schedule 1 - Dictionary.\n\nbeing:\n\n(a) on land in Vietnam; or\n\n(b) at sea in Vietnamese waters;\n\nmeans service in at least one of the areas and at the times described in Items 3A, 3B, 4 and 8 of Schedule 2 of the Veterans' Entitlements Act 1986.\n\n> Note: VEA is also defined in the Schedule 1 – Dictionary.\n\nBMI means W/H2 where:\n\n(a) W is the person's weight in kilograms; and\n\n(b) H is the person's height in metres.\n\ncumulative equivalent dose means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017.\n\n> Note: > Note 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures\n> \n>  involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.\n\n> Note 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.\n\nestuarine Vietnamese waters means at least one of the waterways or harbours in the relevant areas described in Items 4 and 8 of Schedule 2 of the VEA.\n\n> Note: VEA is also defined in the Schedule 1 – Dictionary.\n\ninhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) means:\n\n(a) decanting or spraying;\n\n(b) cleaning or maintaining equipment used to apply;\n\n(c) being sprayed with;\n\n(d) handling or sawing timber treated with;\n\n(e) being in an environment shrouded in dust from timber treated with; or\n\n(f) using cutting oils contaminated with;\n\none of the following chemicals:\n\n(a)2,4,5-trichlorophenoxyacetic acid;\n\n(b) 2,4,5-trichlorophenoxypropionic acid;\n\n(c) 2,4,5-trichlorophenol;\n\n(d) 2-(2,4,5-trichlorophenoxy)-ethyl 2,2-dichloropropionionate;\n\n(e) o,o-dimethyl-o-(2,4,5-trichlorophenyl)-phosphorothioate;\n\n(f) pentachlorophenol;\n\n(g) 2,3,4,6-tetrachlorophenol;\n\n(h) 2,4,6-trichlorophenol;\n\n(i) 1,3,5-trichloro-2-(4-nitrophenoxy)benzene;\n\n(j) 2,4-dichloro-1-(4-nitrophenoxy)benzene; or\n\n(k) 2,4-dichloro-1-(3-methoxy-4-nitrophenoxy)-benzene.\n\nmalignant neoplasm of the prostate see subsection 7(2).\n\nMRCA means the Military Rehabilitation and Compensation Act 2004.\n\none pack-year means the amount of tobacco consumed in smoking 20 cigarettes per day for a period of 1 year, or an equivalent amount of tobacco products.\n\n> Note 1: An equivalent amount of tobacco products is 7,300 grams of smoking tobacco by weight, either in cigarettes, pipe tobacco or cigars, or a combination of same. For pipe tobacco, cigars or combinations of multiple tobacco types, 1 gram of tobacco is considered to be equal to one cigarette.\n\n> Note 2: Pack-years are calculated by dividing the number of cigarettes smoked per day by 20 and multiplying this number by the number of years the person has smoked. For example, smoking 10 cigarettes per day for 10 years is equal to 5 pack-years, and smoking 40 cigarettes per day for 10 years is equal to 20 pack-years.\n\npotable water means water used for drinking water, food preparation and beverage production.\n\nrelevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\n> Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\nsmokeless tobacco means tobacco products without combustion or pyrolysis at the time of use, including chewing tobacco and tobacco snuff but excluding e-cigarettes.\n\nterminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\nVEA means the Veterans' Entitlements Act 1986.\n\n> Note: Endnotes\n\n> Note: Endnote 1—About the endnotes\n\nThe endnotes provide information about this compilation and the compiled law.\n\nThe following endnotes are included in every compilation:\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\nAbbreviation key—Endnote 2\n\nThe abbreviation key sets out abbreviations that may be used in the endnotes.\n\nLegislation history and amendment history—Endnotes 3 and 4\n\nAmending laws are annotated in the legislation history and amendment history.\n\nThe legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.\n\nThe amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.\n\nMisdescribed amendments\n\nA misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.\n\nIf a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.\n\n> Note: Endnote 2—Abbreviation key\n\n| ad = added or inserted                         | orig = original                     |\n| ---------------------------------------------- | ----------------------------------- |\n| am = amended                                   | par = paragraph(s)/subparagraph(s)  |\n| amdt = amendment                               | /sub‑subparagraph(s)                |\n| c = clause(s)                                  | pres = present                      |\n| C[x] = Compilation No. x                       | prev = previous                     |\n| Ch = Chapter(s)                                | (prev…) = previously                |\n| def = definition(s)                            | Pt = Part(s)                        |\n| Dict = Dictionary                              | r = regulation(s)/rule(s)           |\n| disallowed = disallowed by Parliament          | reloc = relocated                   |\n| Div = Division(s)                              | renum = renumbered                  |\n| exp = expires/expired or ceases/ceased to have | rep = repealed                      |\n| effect                                         | rs = repealed and substituted       |\n| F = Federal Register of Legislation            | s = section(s)/subsection(s)        |\n| gaz = gazette                                  | Sch = Schedule(s)                   |\n| LA = Legislation Act 2003                      | Sdiv = Subdivision(s)               |\n| LIA = Legislative Instruments Act 2003         | SLI = Select Legislative Instrument |\n| (md not incorp) = misdescribed amendment       | SR = Statutory Rules                |\n| cannot be given effect                         | Sub‑Ch = Sub‑Chapter(s)             |\n| mod = modified/modification                    | SubPt = Subpart(s)                  |\n| No. = Number(s)                                | underlining = whole or part not     |\n| o = order(s)                                   | commenced or to be commenced        |\n| Ord = Ordinance                                |                                     |\n\n> Note: Endnote 3—Legislation history\n\n| Name                                                                                                                       | Registration                | Commencement    | Application, saving and transitional provisions |\n| -------------------------------------------------------------------------------------------------------------------------- | --------------------------- | --------------- | ----------------------------------------------- |\n| Statement of Principles concerning malignant neoplasm of the prostate (Reasonable Hypothesis) (No. 3 of 2023)              | 3 January 2023F2023L00001   | 23 January 2023 |                                                 |\n| Amendment Statement of Principles concerning factors relating to being in Vietnam (Reasonable Hypothesis) (No. 27 of 2024) | 28 February 2024F2024L00224 | 26 March 2024   |                                                 |\n\n> Note: Endnote 4—Amendment history\n\n| Provision affected                                                                                | How affected       |\n| ------------------------------------------------------------------------------------------------- | ------------------ |\n| Section 2……………….                                                                                  | rep LA s 48D       |\n| Section 4……………….                                                                                  | rep LA s 48C       |\n| Schedule 1 – Dictionary – ' \"being (a) on land in Vietnam; or (b) at sea in Vietnamese waters\"….' | rs. No. 27 of 2024 |","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":5,"scope_assessment":{"changed":false,"description":"The instrument maintains its original scope as a specific medical determination for prostate cancer under the reasonable hypothesis pathway. The 2024 amendment updated the Vietnam service definitions to align with changes in the parent VEA Schedule 2, but did not expand the substantive scope beyond the original intent of establishing service connection factors for this specific condition."},"complexity_factors":["13 distinct factors with varying temporal requirements (5-year, 10-year, 20-year lookback periods)","Nested definitions requiring cross-reference to Schedule 1 (e.g., 'being exposed to arsenic as specified' expands to 3 sub-criteria)","Specific quantitative thresholds (1,000 hours, 400g/day, 0.1 sievert, 10 pack-years, 50 micrograms/litre)","Conditional logic in factors 9 and 10 (cessation clauses — if smoking/tobacco stopped, worsening must occur within 20/10 years)","Bifurcated application: factors 1-7 for onset vs. factors 8-13 for worsening only, with additional restriction in section 10(2)","Cross-references to external legislation (VEA Schedule 2 for Vietnam service areas, MRCA for service definitions)","Technical medical terminology requiring definition (ICD-10-AM codes, hexavalent chromium, TCDD, prostatic intraepithelial neoplasia)","Mathematical formulas for BMI and pack-years with conversion notes for non-cigarette tobacco"],"plain_english_summary":"This instrument sets the medical rules for when Australian veterans can claim prostate cancer as service-related under the Veterans' Entitlements Act and Military Rehabilitation and Compensation Act. It identifies specific service‑ and exposure‑related risk factors that, if met, create a legal presumption linking prostate cancer to military service for onset or for clinical worsening.\n\nThat presumption uses the generous \"reasonable hypothesis\" test, so affected veterans may get automatic acceptance of claims rather than needing stronger proof."},"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":false,"description":"This compilation incorporates a factual amendment clarifying the meaning of service \"being on land in Vietnam; or at sea in Vietnamese waters\" (see endnotes and Schedule 1). That is a definitional/territorial clarification rather than a substantial expansion of the SOP’s purpose. The instrument remains focused on listing factors that raise a reasonable hypothesis connecting prostate cancer to relevant service. It has not grown significantly beyond that original, stated purpose."},"complexity_factors":["Multiple exposure factors (13 distinct factors in section 9) with different numeric thresholds and lag periods","Schedule 1 contains numerous defined terms used across the instrument (around 15 key definitions: BMI, cumulative equivalent dose, pack‑year, smokeless tobacco, potable water, Vietnam service definitions, TCDD exposure activities, arsenic exposure specifications, etc.)","Different reference events (\"clinical onset\" vs \"clinical worsening\") with different temporal tests and cessation windows (sections 7, 9 and 10)","Cross-references to external technical material (ICD‑10‑AM code, ARPANSA guide for dose calculation) requiring outside methodology","Cross-references to other instruments and parts of the VEA (Schedule 2 items defining Vietnam areas; section 11 linking to other SOPs)","Mixture of occupational, environmental and lifestyle risk factors producing mixed evidentiary types (medical records, service records, environmental monitoring, dietary history)","Numeric dose and duration thresholds that require retrospective quantification (e.g. 0.1 sievert, 1,000 hours of TCDD-related exposure, 400 g/day dairy)","Amendment history and potential uncommenced or modifying amendments noted in compilation (endnotes), increasing interpretive work for users"],"plain_english_summary":"**What this instrument does (mechanics first)**\n\n- This is a Statement of Principles (SOP) issued under the Veterans' Entitlements Act 1986. It sets out the specific factors that, if present, are sufficient to raise a \"reasonable hypothesis\" that a person's malignant neoplasm of the prostate (prostate cancer) or death from it is related to their relevant military service (see sections 3, 5, 7 and 9).\n\n- The SOP does not itself grant payments. Instead, it is the medical-causal standard the Department of Veterans' Affairs (DVA) and decision-makers use when assessing claims under the VEA (section 120A) or the Military Rehabilitation and Compensation Act (section 338). If at least one listed factor is established and related to the person’s relevant service (section 9 and section 10), that meets the statutory threshold of a \"reasonable hypothesis\" for service connection.\n\n**Who this affects**\n\n- Veterans, former members of the Australian Defence Force and certain other entitled groups making claims for prostate cancer or death from prostate cancer under the VEA or MRCA (section 5).  \n- Medical practitioners and experts asked to provide evidence about exposures, diagnoses, dates and doses.  \n- The Department of Veterans' Affairs and the Repatriation Medical Authority (RMA), who rely on this SOP to decide causation.  \n- Where factors refer to workplace exposures (for example hexavalent chromium or arsenic), private employers or industry records may become relevant to proof, but the SOP itself does not create employer liabilities—it is evidence used in veterans’ entitlement assessments.\n\n**What factors are treated as raising a reasonable hypothesis (summary of section 9 and Schedule 1)**\n\nAt least one of the following must be present and related to relevant service to raise a reasonable hypothesis:\n\n- Significant exposure to TCDD-contaminated chemical agents (examples include handling or being sprayed with specified chlorophenoxy chemicals or timber treated with pentachlorophenol)—with defined exposure activities in the Dictionary (Schedule 1).  \n- Service in Vietnam (on land or at sea) or drinking potable water on vessels using evaporative distillation of estuarine Vietnamese waters, for a cumulative 30+ days (with at least a 5‑year lag to clinical onset).  \n- Consuming an average of at least 400 g/day of dairy products for 5 years within the 20 years before clinical onset.  \n- Specified arsenic exposure (e.g. drinking water averaging ≥50 µg/L for ≥10 years, or equivalent cumulative intake, or clinical evidence of chronic arsenic toxicity).  \n- Working with high concentrations of hexavalent chromium exposures for a cumulative ≥1,500 hours (with a 5‑year lag).  \n- Receiving a cumulative equivalent ionising radiation dose to the prostate of ≥0.1 sievert (with a 5‑year lag), using ARPANSA dose‑reconstruction methodology.  \n- Periodontitis of specified duration.  \n- Alcohol consumption of ≥100 kg in any 10‑year period before clinical worsening.  \n- Smoking ≥10 pack‑years, starting ≥5 years before clinical worsening (and with “worsening” falling within 20 years of cessation if smoking has stopped).  \n- Regular use of smokeless tobacco for ≥10 years (with a 10‑year cessation window).  \n- Obesity (BMI ≥30 or specified waist measures) for at least 5 years within the 20 years before clinical worsening.  \n- Diabetes mellitus for ≥5 years before clinical worsening.  \n- Inability to obtain appropriate clinical management for prostate cancer.\n\nNotes on definitions and timing: the SOP distinguishes \"clinical onset\" from \"clinical worsening\" and imposes differing lag periods and cumulative thresholds depending on the factor (see section 9 and Schedule 1). It also excludes certain tumour types from the meaning of \"malignant neoplasm of the prostate\" (subsection 7(2)(c)).\n\n**Official rationale and the instrument's stated basis**\n\n- The RMA states there is \"sound medical‑scientific evidence\" that links prostate cancer and death from it to relevant military service (section 8). The SOP translates that view into a list of measurable exposures, durations and dose thresholds that will, if proved and related to service, meet the statutory causation threshold.\n\n**How this matters practically — costs, incentives and trade‑offs**\n\n- Who pays: benefits that flow from establishing service connection are paid from Commonwealth funds administered by DVA; the SOP informs which claimants will plausibly qualify (sections 5 and 9).  \n- Who decides: the RMA issues the SOP and DVA decision-makers apply it to claims. Medical examiners and expert witnesses provide the evidence to demonstrate the listed factors and their timing.  \n- Evidence and administrative burden: many factors require quantifiable proof (e.g. cumulative hours, pack‑years, sieverts, dairy grams per day, water arsenic concentrations). Some require dose reconstruction or verification against external technical guidance (the ARPANSA methodology for cumulative equivalent dose in Schedule 1). That creates administrative work for claimants and for DVA—to collect service records, occupational histories, medical records, environmental monitoring data and expert reports.  \n- Implementation risk and uncertainty: dose reconstruction (ionising radiation) and retrospective quantification of chemical or dietary exposures are technically demanding and can be contentious, increasing appeals or requests for further medical opinion.  \n- Compliance and discretion: the SOP sets objective numeric thresholds, which reduces some case‑by‑case discretion, but decision-makers still must judge whether an applicant has proved the factor and that it was related to relevant service (section 10). When a factor refers to an injury/disease already treated by another SOP, the other SOP controls that part (section 11), adding cross‑SOP dependency.  \n- Effects on private choice and enterprises: the SOP increases the evidentiary value of certain workplace exposures (e.g. chromium VI, arsenic) for veterans’ claims. That may increase demand for employer records, but it does not itself change employers’ statutory safety duties or civil liability—those remain governed by workplace and tort law. Some industries with historical use of listed chemicals may see a higher concentration of veterans’ claims linked to past work.  \n- Concentrated benefits and diffuse costs: the beneficiaries are a defined group of veterans with proven exposures; costs are borne by the public purse and are therefore diffuse across taxpayers.  \n- Potential for contested or borderline cases: factors tied to common lifestyle exposures (dairy consumption, alcohol, obesity, smoking) could complicate the causal picture if multiple risk factors are present. The SOP addresses this by limiting some lifestyle factors to material contribution or aggravation where the disease pre‑existed service (section 10(2)).\n\n**Key implementation details to note**\n\n- Different factors use different reference events (\"clinical onset\" versus \"clinical worsening\"). Timing requirements vary (5, 10, or 20 years) and some factors require cumulative exposure measures (hours, pack‑years, sieverts, grams/day). See section 9 and Schedule 1 for the exact thresholds.  \n- The SOP refers to external standards and material (ICD‑10‑AM code C61 and ARPANSA guidance for dose calculations). These external references are part of how claims are evaluated (subsection 7(3) and Schedule 1 definition of cumulative equivalent dose).  \n\n**Practical takeaways for a claimant or adviser**\n\n- To rely on this SOP a claimant must show one of the listed factors and connect it to their relevant service (section 9 and section 10).  \n- Gather service records that show location/timing (for Vietnam service), occupational history (for chromium or TCDD exposures), medical records (diagnosis dates, periodontitis, diabetes), and lifestyle histories (smoking, alcohol, BMI, dairy consumption).  \n- For radiation exposure or complex environmental exposures, expect that dose reconstruction or specialist reports will be required (Schedule 1 references ARPANSA methodology)."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-prostate-reasonable-hypothesis-no-3-of-","history":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-prostate-reasonable-hypothesis-no-3-of-/history","analysis":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-prostate-reasonable-hypothesis-no-3-of-/analysis","conflicts":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-prostate-reasonable-hypothesis-no-3-of-/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-prostate-reasonable-hypothesis-no-3-of-/important-cases","documents":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-prostate-reasonable-hypothesis-no-3-of-/documents"}}